RecruitingNCT07582354

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

520 participants

Start Date

Oct 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance. The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age 18+
  • Signed CI for study partecipation and personal data processing.
  • Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS AOU Policlinico Sant'Orsola

Bologna, Bo, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07582354


Related Trials